U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT06811272) titled 'Outpatient Epcoritamab As 2L in NTE R/R DLBCL' on Jan. 31.
Brief Summary: The purpose of this study is to measure the efficacy of the study drug, epcoritamab, in participants with relapsed/refractory large B-cell lymphoma.
Study Start Date: July 16, 2025
Study Type: INTERVENTIONAL
Condition:
Relapsed Large B-cell Lymphoma
Refractory Large B-cell Lymphoma
Intervention:
DRUG: Epcoritamab
Bispecific IgG1 antibody
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Massachusetts General Hospital
Information provided by (Responsible Party): Julie E. Haydu, MD, PhD, Massachusetts General Hospital
Published by HT Digital Content Serv...